Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Executive Summary
The 21st Century Cures bill made it through the US Congress in 2016 after all; advocates can thank the unexpected presidential victory of Donald Trump for helping to make that happen.
Like many prominent Republicans, House Energy & Commerce Committee Chairman Fred Upton was not excited when the party selected Donald Trump as its presidential candidate. In fact, he very publicly declined to endorse Trump ahead of the GOP convention and just as publicly called on him to drop out of the race in October after the Access Hollywood video was released.
But, now that Upton’s 21st Century Cures bill is on its way to President Obama for signature, the Michigan Republican should probably send Trump a thank-you note.
Upton launched the Cures effort in 2014 and shepherded it through the House in 2015, eager to complete work before his tenure as E&C Committee chair ends with the adjournment of the current Congress.
Heading into election day, the chances that Upton would be able to celebrate the accomplishment were looking bleak. The Senate had repeatedly missed deadlines to bring a companion bill to the floor for a vote, with the final hope a promise to take up the bill in the post-election “lame duck” session.
Find out more about Medtech Insight here
In Vivo: strategic insights for life sciences decision-maker...
Pharma Intelligence offers a wealth of pharmaceutical industry news and strategic insight into the healthcare & biotechnology markets from around the world. Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.
Scrip: industry news and insights
The Swiss major's pharma chief tells Scrip that its gene therapy for SMA offers much more than Biogen's Spinraza for both patients and payers, noting that the company is ready with alternative payment models for the pricey treatment as soon as approvals for Zolgensma are granted.
Topics Business strategies Drug approval Drug development landscape Drug review
Scrip: industry news and insights
By Emily Hayes
In second Phase III diabetes study to report, oral GLP-1 agonist semaglutide misses some weight loss goals when compared with Boehringer/Lilly's SGLT-2 inhibitor Jardiance.
Request a Demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Get a window into what the leading players across the biopharma, medtech, and diagnostics industries are thinking, as well as important insight into what your competitors are doing. Build your strategy with In Vivo.
In the continually evolving medtech competitive landscape, it is vital to stay up-to-date with key events. With Meddevicetracker, you’ll be able to anticipate upcoming filings, research clinical trial dates and data, and access market size information and expert forecasts, all in one place.
Looking for more products Product Finder
